Inactive Instrument

News Loxo Oncology Inc

Equities

US5488621013

Summary

Unlock all the news: Be the first to know and act before the market!

Loxo Oncology : Merus Enters Collaboration With Eli Lilly To Develop New Generation Of Cancer Treatments	21-02-05	AQ
Eli Lilly and : Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma	20-12-08	AQ
Eli Lilly and : Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting	19-12-09	AQ
Bayer : gains full Vitrakvi rights from Eli Lilly's Loxo	19-02-15	RE
Loxo Oncology : Lilly Completes Acquisition of Loxo Oncology	19-02-15	PR
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction	19-02-01	GL
GlaxoSmithKline : to look for early-stage assets - CEO	19-01-08	RE
Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy	19-01-07	RE
Amazon and Netflix push Wall Street higher	19-01-07	RE
Lilly Announces Agreement To Acquire Loxo Oncology	19-01-07	GL
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305	18-12-21	GL
Bayer : Lower drug sales potential at Bayer underscores need for deals	18-12-05	RE
Bayer : Lower drug sales potential at Bayer underscores need for deals	18-12-05	RE
FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2)	18-11-26	GL
Bayer : Roche takes on Loxo, Bayer in gene-defined cancer class	18-10-21	RE
Loxo Oncology : Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types	18-10-21	PR
Loxo Oncology Announces Larotrectinib Clinical Update in Patients with TRK Fusion Cancers at the European Society for Medical Oncology 2018 Congress	18-10-21	GL
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer	18-10-15	GL
Loxo Oncology Announces Details for Data Presentations at the European Society for Medical Oncology 2018 Congress	18-10-09	GL
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association	18-10-06	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Loxo Oncology Inc

Equities

US5488621013

Summary

Filters